Evaluation of Human Papillomavirus Vaccine Coverage in Girls and Young Women With Chronic Disease (NCT06158802) | Clinical Trial Compass
CompletedNot Applicable
Evaluation of Human Papillomavirus Vaccine Coverage in Girls and Young Women With Chronic Disease
France223 participantsStarted 2024-01-23
Plain-language summary
The main objective of the study is to determine the vaccination coverage rate for human papillomavirus in adolescents aged 11 to 20 with chronic disease and treated at the Necker-Enfants Malades Hospital, compared to a population witnessed adolescent girls aged 11 to 20 years without chronic disease.
Who can participate
Age range11 Years – 20 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Information and non-opposition of major patients and holders of parental authority of minor patients and minor patients
* Girls and young women aged 11 to 20
* To be followed at the Necker-Enfants Malades Hospital ("chronic condition" group)
* To be followed at the Specialized Medical Center for Children and Adolescents ("control" group)
* Have a chronic condition ("chronic condition" group) :
* Diabetes type 1
* Metabolic diseases
* Patients followed in immuno-hematology
* Cystic Fibrosis
* Sickle
* Kidney transplant
* Heart Disease
* Inflammatory bowel diseases
* Rare anorectal and pelvic anomalies
* Live in France
* Comprehension of the French language (oral and written)
Exclusion Criteria:
* Have a contraindication to the HPV vaccine - Gardasil 9 (Vidal Hoptimal, 2018)
* Have a contraindication to the HPV vaccine - Gardasil (Vidal Hopitmal, 2018)
* Have a contraindication to HPV vaccine - Cervarix (Vidal Hoptimal, 2018)
What they're measuring
1
Immunization coverage rate for human papillomavirus vaccine